News | January 11, 2026
Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
Subscribe To Our Newsletter & Stay Updated
